ANI Pharma (ANIP) Tops Q1 EPS by 12c, Offers FY16 Guidance

ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $0.76, $0.12 better than the analyst estimate of $0.64. Revenue for the quarter came in at $20.6 million versus the consensus estimate of $21.03 million.

GUIDANCE:

ANI Pharma sees FY2016 EPS of $3.54-$3.91, versus the consensus of $3.41. ANI Pharma sees FY2016 revenue of $119-134 million, versus the consensus of $117.87 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• BofA lists top 5 themes driving next $1tn in incremental semi sales